BI 836826

Drug Profile

BI 836826

Alternative Names: BI-836826; mAb 37.1; mAb 37.2

Latest Information Update: 10 May 2017

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Developer Boehringer Ingelheim; Gilead Sciences
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD37 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diffuse large B cell lymphoma
  • Phase I/II Chronic lymphocytic leukaemia
  • Phase I Non-Hodgkin's lymphoma

Most Recent Events

  • 19 Apr 2017 BI 836826 is still in phase I trials for Chronic lymphocytic leukaemia (Monotherapy, Second-line therapy or greater, Late-stage disease) in Germany (NCT01296932)
  • 31 Mar 2017 Boehringer Ingelheim suspends patient recruitment in a phase I trial in Non-Hodgkin's lymphoma in South Korea (NCT01403948)
  • 03 Dec 2016 Pharmacodynamics data from a preclinical study in Diffuse large B-cell lymphoma presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-2016) 3219772)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top